Answers are grounded in this paper and cite their sources.
Demonstrates a robust UPLC method for Olaparib, indicating improved reliability and efficiency.
A systematic, in silico-assisted Analytical Quality by Design (AQbD) strategy was applied to develop a robust, stability-indicating reverse-phase ultra-performance liquid chromatography (UPLC) method for the simultaneous quantitative determination of Olaparib and its six related impurities in pharmaceutical dosage forms. Method development integrated limited, strategically designed experimental data with retention modeling and design of experiments (DoE) principles using Plackett–Burman screening (n = 8) followed by a 3 × 2 × 2 full factorial design (n = 12) to comprehensively understand the chromatographic behavior. Critical method parameters (CMPs) influencing separation performance were identified, and a method-operable design region (MODR) was established to ensure consistent and reliable method performance. The optimized conditions (pH 2.5, 50 °C, 15-min gradient time) achieved baseline resolution (Rs ≥ 2.0) for all impurity pairs with a total run time of 15 min, representing a 40% reduction compared to initial scouting gradients. Excellent correlation between in-silico predictions and experimental results [R2 = 0.9998, RMSE = 0.16 min] confirmed the strong predictive capability of the applied modeling approach. Overall, the proposed in silico-assisted AQbD framework substantially reduced experimental trials by approximately 60% relative to conventional one-factor-at-a-time optimization, improved process understanding, and ensured method robustness in alignment with current regulatory expectations including ICH Q14 and Q2(R2).
No takes yet. Share an insight, caveat, or question.
Dokewar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: